Scarica l'app Stockscreener
5.38
0.19%
-0.010
Dopo l'orario di chiusura:
5.39
0.010
+0.19%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World
Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq
Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire
Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed - StockTitan
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks
Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Jasper Therapeutics, Inc. SEC 10-K Report - TradingView
Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India
Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa
Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire
Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan
Jasper Therapeutics Reports Promising Clinical Progress - TipRanks
Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks
Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks
Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail
Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times
Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail
Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq
JSPR stock touches 52-week low at $5.22 amid market challenges - Investing.com Nigeria
Objective long/short (JSPR) Report - Stock Traders Daily
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Jasper Therapeutics Announces Presentations of Briquilimab Data at AAAAI 2025 Annual Meeting - Nasdaq
JSPR’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle
Selling Buzz: Jasper Therapeutics Inc [JSPR] Chief Operating Officer Mahal Jeetinder Singh sells 900 shares of the company – Knox Daily - Knox Daily
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire
Knightscope Achieves Full FedRAMP® Authorization, Unlocking Federal Growth - The Globe and Mail
Inside Jasper's Revolutionary Mast Cell Therapy: Key Updates Coming at Major Healthcare Conference - StockTitan
Jasper Therapeutics Inc (NASDAQ:JSPR) Drops -9.55%, But A Strong Recovery May Be Imminent - Marketing Sentinel
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
How to Take Advantage of moves in (JSPR) - Stock Traders Daily
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $67.75 - Defense World
Insider Selling in Tech Stocks Spikes in Q4 - The Globe and Mail
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Cantor Fitzgerald Forecasts JSPR FY2025 Earnings - Defense World
Research Analysts Set Expectations for JSPR FY2025 Earnings - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Barclays PLC - Defense World
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):